Latest Macula Stories
SARATOGA, Calif., March 30 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (AMD), today announced the FDA Ophthalmic Devices Advisory Panel unanimously recommended that the FDA approve, with conditions, the premarket application (PMA) for its implantable telescope for End-Stage AMD.
An Australian study suggests a diet heavy in red meat may increase the risk of age-related macular degeneration, a leading cause of blindness. The report, published in the American Journal of Epidemiology, said people who eat 10 or more portions of red meat each week are nearly 50 percent more likely to experience deterioration of the retina. Substituting chicken at least three times a week reduces the risk by more than 50 percent, Britain's Telegraph newspaper reported Thursday. Macular...
Researchers are working to shed new light on the most common form of blindness among adults, and their findings are suggesting an innovative way forward for treatment.
A layer of "dark cells" in the retina that is responsible for maintaining the health of the light-sensing cells in our eyes has been imaged in a living retina for the first time.
A new study from Georgia Tech shows that when patients with macular degeneration focus on using another part of their retina to compensate for their loss of central vision, their brain seems to compensate by reorganizing its neural connections.
SARATOGA, Calif., Nov.
CUMBERLAND, R.I., Oct.
We're all guilty of taking our eyesight for granted. As you read this, some of you will wear glasses, some of you will wear contact lenses - but almost all of you will be unable to imagine not being able to read the headline on this page.
HOUSTON, Sept. 10 /PRNewswire/ -- A landmark study at five university-based research centers found that TOZAL(R), a patented combination of antioxidants and micronutrients, enabled patients with "dry" macular degeneration to improve their vision.
LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S.
More Images (2 images) »